Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Gilead Sciences
H. Lee Moffitt Cancer Center and Research Institute
Eastern Cooperative Oncology Group
St. Jude Children's Research Hospital
Novartis
Vanderbilt-Ingram Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Swiss Cancer Institute
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Marker Therapeutics, Inc.
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
University Hospital, Lille
TC Biopharm
Sanofi
Institut Curie
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Washington University School of Medicine
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
University of Miami
Columbia University
Thomas Jefferson University
University of California, Davis
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Syros Pharmaceuticals
National Cancer Institute (NCI)
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Malattie EMatologiche dell'Adulto
University of Florida
Zhejiang DTRM Biopharma
Fred Hutchinson Cancer Center
Washington University School of Medicine
Beijing Boren Hospital
Ensoma
Academic and Community Cancer Research United
Astex Pharmaceuticals, Inc.
Prolacta Bioscience
Institute of Hematology and Blood Transfusion, Czech Republic
Loyola University
TG Therapeutics, Inc.
Fred Hutchinson Cancer Center
University Hospital Regensburg
Technische Universität Dresden